GU Oncology Now

?? The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before #docetaxel against docetaxel monotherapy in patients with metastatic castration-resistant #prostatecancer. ?? Learn how the combination can improve antitumor activity:

Discover why #DSUIOnTheBeach25 is the go-to event for forward-thinking urologists. This isn't just another conference—it's a catalyst for practical innovation. Key focus areas for 2025: ??Men's Health: TRT Challenges and Multidisciplinary Approaches ??Kidney Cancer: From Imaging to Adjuvant Therapy ??Reconstructive Urology: Robotic Surgery and Complex Cases ??Prostate Cancer: Early Detection to Advanced Management ??BPH/Endourology: Latest Advances in Stone Management ??Bladder Cancer: From BCG-Unresponsive NMIBC to MIBC Treatment ??The Future of Urology: Emerging Trends and Technologies ??Translational Urology: Bridging Research and Clinical Practice ??Florida Urological Society Highlights: From AI to Private Equity Beyond the sessions, engage in beachside networking that fosters lasting professional relationships. And yes, bring your family too! Visit our events page for registration details and full program information: https://loom.ly/i95Ediw

??ImmunityBio, Inc. has announced promising updates from its QUILT 3.032 trial, marking the enrollment of its 100th patient with BCG-unresponsive NMIBC CIS. ?? Learn more about the trial, which has shown a 71% CR rate among participants:

? In our new star-studded roundtable, moderator Katy Beckermann and guests Sumanta Pal, MD, FASCO, Toni Choueiri, Hans Hammers, and Pedro C Barata, MD MSc FACP, discuss ICIs and TKIs in #RCC and the impact of these strategies on treatment. ?? Watch the first part now, which focuses on the differences between the TiNivo-2 and CONTACT-3 trials: https://buff.ly/3Zkg6bF

?? While VEGF TKIs are a common therapy for the treatment of metastatic #ccRCC, VEGF upregulation can occur as a resistance measure against the treatment. ?? In a study presented at #IKCS by Dr. Saby George of Roswell Park Comprehensive Cancer Center, researchers hypothesized that utilizing #bevacizumab during breaks in #pazopanib treatment can result in less toxicity while binding and neutralizing VEGF:

?? Clarity Pharmaceuticals has begun their trial comparing the diagnostic efficacy of 64Cu-SAR-bisPSMA, against the current standard-of-care, 68Ga-PSMA-11, in detecting #prostatecancer recurrence. ?? Learn more about the trial's goals and the advantages of 64Cu-SAR-bisPSMA:

?? In the second part of our interview with Drs. Michael Whalen and Vincent Xu of The George Washington University Cancer Center, Dr. Xu discusses the next steps for their study on NAC for UTUC, along with potential alternative treatments for patients who are ineligible for chemotherapy. ?? Watch the full video here: https://buff.ly/4hUtxrc

?? While the PIVOT-02 trial found that #BEMPEG plus #nivolumab displayed benefits over ICI monotherapy for patients with advanced urothelial carcinoma, PIVOT-10 showed that the combination did not meet the efficacy threshold for ORR in the study’s patient population. Learn more:

?? A recent study led by Justin Refugia of Wake Forest University School of Medicine sought to determine if sequential intravesical chemotherapy with #gemcitabine and #docetaxel provides similar oncologic outcomes to BCG in patients with treatment-na?ve, HR NMIBC. ?? Learn how the treatment can potentially aid patients during the ongoing BCG shortage:

?? We spoke with Drs. Michael Whalen and Vincent Xu of The George Washington University Cancer Center on their recent analysis of neoadjuvant chemotherapy utilization for UTUC and the differences between radical nephroureterectomy and NAC as perioperative treatments. ?? Watch part one of this interview: